ImmunityBio Executive and Leadership Team

Frank Jones, the Chairman & Chief Executive Officer at ImmunityBio, directs the overarching strategy and operational execution for the company's development of next-generation therapies and vaccines. This leadership role involves guiding the organization's mission to bolster the natural immune system for combating cancers and infectious diseases. Frank Jones oversees the integration of immunotherapy and cell therapy platforms, ensuring their combined action drives and sustains immune responses for durable disease protection. The Chairman & Chief Executive Officer is responsible for advancing the company's pipeline, including ANKTIVA, the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS, and other potential cancer vaccines. This executive ensures the scientific and business strategies align with the goal of creating more effective, accessible, and easily administered treatments than current standards of care in oncology and infectious diseases, thereby shaping the future of patient care.

Enrique Diloné, the Chief Technology Officer at ImmunityBio, architects the technological infrastructure and innovation pipeline for the company's groundbreaking therapies and vaccines. This executive spearheads the advancement of immunotherapy and cell therapy platforms, ensuring their seamless integration and optimal performance in bolstering the natural immune system. Enrique Diloné drives the research and development efforts focused on creating durable and safe protection against cancers and infectious diseases. The Chief Technology Officer oversees the technical aspects of developing next-generation treatments, including potential cancer vaccines and immunotherapies designed to reduce or eliminate the need for high-dose chemotherapy. By focusing on accessibility and ease of administration, this leadership role ensures ImmunityBio's technological solutions meet and exceed current standards of care, positioning the company at the forefront of biotechnological advancement in oncology and infectious disease treatment.

Sarah Singleton, the Chief Communications Officer & Head of Patient Advocacy at ImmunityBio, shapes and disseminates the company's narrative, ensuring clear communication of its mission and scientific advancements. This executive leads external and internal communications strategies, highlighting ImmunityBio's commitment to developing next-generation therapies and vaccines that enhance the natural immune system. Sarah Singleton champions patient advocacy, fostering strong relationships with patient communities and ensuring their perspectives inform the company's development of treatments for cancers and infectious diseases. The Chief Communications Officer & Head of Patient Advocacy oversees the messaging around groundbreaking products like ANKTIVA, emphasizing their role in creating durable and safe protection. This leadership position ensures that the accessibility and efficacy of ImmunityBio's innovative platforms are effectively communicated to stakeholders, including healthcare professionals, investors, and the public, reinforcing the company's impact on patient lives.

Leonard Sender, the Chief Medical Officer, Liquid Tumors & Cell Therapy at ImmunityBio, directs clinical development strategies for novel immunotherapies and cell therapies targeting liquid tumors. This executive oversees the clinical trial design and execution, focusing on harnessing the natural immune system to combat these challenging diseases. Leonard Sender's leadership is critical in advancing the company's pipeline, including the development of potential cancer vaccines and cell-based treatments aimed at providing durable and safe protection. The Chief Medical Officer, Liquid Tumors & Cell Therapy ensures that clinical programs align with the company's goal of creating more effective and accessible treatments, potentially reducing the need for traditional chemotherapy. This role involves close collaboration with regulatory bodies, including the FDA, to expedite the approval process for groundbreaking therapies like ANKTIVA, thereby driving significant advancements in oncology care.